A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

NCT05353205 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

CML, Chronic Phase

Interventions

DRUG: Flumatinib mesylate tablets (400mg)
DRUG: Flumatinib mesylate tablets (600mg)

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.